Identifying Dihydropyrimidine Dehydrogenase as a Novel Regulator of Hepatic Steatosis. Homo sapiens

5-FU (5-Fluorouracil), CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9), DPYD (dihydropyrimidine dehydrogenase), FASN (fatty acid synthase), FXR (farsenoid X receptor), G0S2 (G0/G1 Switch Gene 2), HMGCS1 (3-Hydroxy-3-Methylglutaryl-CoA Synthase 1), HSD17B13 (hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13), MID1IP1 (MID1 interacting protein 1), NAFLD (nonalcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), PHH (primary human hepatocyte), PNPLA3 (Patatin Like Phospholipase Domain Containing 3), TXNIP (thioredoxin interacting protein 1), UPP1 (uridine phosphorylase-1)